ceh-14 Antibody

What is CEH-14 and why is it important in C. elegans research?

CEH-14 is a LIM homeodomain transcription factor in C. elegans that serves as the ortholog of vertebrate Lhx3/Lhx4 genes . It plays critical roles in neurite outgrowth and phasmid function, with expression documented in several neuronal populations including PHB, PHC, PVC, PVN, PVQ, and PVW . The protein's study is significant because it reveals fundamental mechanisms of neuronal development, tissue-specific gene regulation, and transcriptional control networks in a model organism with relevance to understanding conserved developmental pathways.

What expression patterns does CEH-14 exhibit in C. elegans?

CEH-14 exhibits a complex, multi-tissue expression pattern in C. elegans. Reporter constructs show CEH-14 expression in:

• Head and tail neurons

• Spermatheca

• Hypodermis (with a distinctive gradient pattern)

The hypodermal expression is particularly interesting as it forms a gradient that is strongest in the central body region in L4 to young adult hermaphrodites . In males, which have different gonadal organization, the expression gradient is strongest in the tail region . This sexually dimorphic expression pattern suggests gonad-dependent regulation, as confirmed by laser ablation experiments showing that removal of gonadal precursor cells eliminates ceh-14 reporter expression in hermaphrodite hypodermis .

How do I validate the specificity of a CEH-14 antibody?

For proper validation of a CEH-14 antibody, implement a multi-step approach:

• Pre-absorption test: Incubate the antibody with purified CEH-14 peptide before immunostaining. The absence of immunosignals after pre-absorption indicates antibody specificity, as demonstrated in phoenixin-14 antibody validation .

• Western blot analysis: Verify that the antibody detects a single band of the expected molecular weight in wild-type samples, with reduced or absent signal in ceh-14 mutants.

• Immunohistochemistry pattern comparison: Compare antibody staining patterns with established ceh-14 reporter expression, ensuring concordance with known expression in neurons, spermatheca, and hypodermis .

• Negative controls: Include ceh-14 null mutants or RNAi knockdown samples to confirm signal reduction or elimination.

How can CEH-14 antibodies be used in ChIP-seq experiments?

CEH-14 antibodies are valuable tools for Chromatin Immunoprecipitation sequencing (ChIP-seq) experiments to identify genome-wide binding sites of this transcription factor. Based on previous transcription factor ChIP-seq studies in C. elegans, a methodological approach would include:

• Cross-linking: Fix protein-DNA interactions in worm populations at specific developmental stages (embryonic, L1, L3, L4) using formaldehyde.

• Chromatin preparation: Lyse worms, sonicate chromatin to 200-300bp fragments, and verify fragmentation by gel electrophoresis.

• Immunoprecipitation: Incubate chromatin with CEH-14 antibody bound to magnetic beads, followed by stringent washing to remove non-specific interactions.

• Library preparation and sequencing: Process immunoprecipitated DNA into sequencing libraries and perform high-throughput sequencing.

• Data analysis: Identify CEH-14 binding sites by comparing to input control, as demonstrated in previous C. elegans ChIP-seq studies that identified CEH-14 binding regions in its own promoter .

Such experiments have revealed that CEH-14 potentially binds to several regions of its own promoter (A1, A3, and C1 regions), suggesting autoregulation .

What immunohistochemistry protocols work best for CEH-14 detection in C. elegans tissues?

For optimal CEH-14 detection in C. elegans tissues using immunohistochemistry:

• Fixation: Fix worms in 4% paraformaldehyde for 30-45 minutes at room temperature, which preserves tissue morphology while maintaining epitope accessibility.

• Permeabilization: Treat with collagenase or β-mercaptoethanol to enhance antibody penetration through the cuticle, followed by incubation in blocking buffer containing 1-5% BSA or normal serum.

• Primary antibody incubation: Apply validated CEH-14 antibody at optimized dilution (typically 1:200-1:1000) and incubate overnight at 4°C.

• Secondary antibody: Use fluorophore-conjugated secondary antibodies matching the host species of the primary antibody, typically at 1:200-1:1000 dilution.

• Mounting and imaging: Mount specimens in anti-fade medium containing DAPI for nuclear counterstaining, then image using confocal microscopy to capture the gradient expression pattern in hypodermis and the discrete neuronal expression .

For visualizing the distinctive gradient expression in the hypodermis, confocal z-stacks with appropriate optical sectioning are recommended to clearly distinguish hypodermal staining from underlying tissues.

How can I investigate the role of gonadal signaling in regulating CEH-14 expression?

To investigate the non-cell-autonomous regulation of CEH-14 by gonadal signaling:

• Laser ablation experiments: Target gonadal precursor cells (Z1 and Z4) in early L1 larvae expressing ceh-14 reporter constructs, then assess reporter expression in L4/young adults. This approach has demonstrated that gonadal ablation eliminates the hypodermal expression of ceh-14 reporters .

• Genetic perturbation: Analyze ceh-14 reporter expression in mutants with altered gonadal development or signaling. Previous experiments tested lin-3, egl-17, and lin-12 mutations but found that these pathways do not affect ceh-14 reporter expression .

• RNA-seq analysis: Compare transcriptomes of isolated hypodermis from intact worms versus gonad-ablated worms to identify potential signaling mediators.

• Proximity labeling: Use TurboID or APEX2 fused to CEH-14 in the hypodermis to identify interacting proteins that might mediate gonadal signaling responses.

• Tissue-specific rescue experiments: Express CEH-14 under tissue-specific promoters in ceh-14 mutants to determine which expression domains are sufficient for phenotypic rescue.

This research direction is particularly compelling since traditional signaling pathways (lin-3, egl-17, lin-12) do not affect ceh-14 expression, suggesting novel signaling mechanisms remain to be discovered .

What approaches can be used to identify direct transcriptional targets of CEH-14?

To identify direct transcriptional targets of CEH-14, implement an integrated multi-omics approach:

• ChIP-seq analysis: Perform CEH-14 ChIP-seq at multiple developmental stages to identify genomic binding sites. Previous ChIP-seq studies have identified potential CEH-14 binding sites, and a similar approach can identify direct targets .

• RNA-seq in ceh-14 mutants: Compare transcriptomes between wild-type and ceh-14 mutant animals to identify genes with altered expression. Target tissues should include neurons, hypodermis, and spermatheca where CEH-14 is expressed.

• Integration with modENCODE data: Correlate CEH-14 binding sites with other transcription factors and chromatin marks from modENCODE. Previously, CEH-14 ChIP-seq data identified ~50 potential target genes expressed in the spermatheca and 84 in the hypodermis, with 23 expressed in both tissues .

• Motif analysis: Analyze CEH-14 binding sites to identify consensus DNA recognition motifs, which can be used to predict additional targets genome-wide.

• Reporter assays: Generate transcriptional reporters for candidate target genes and test if their expression is altered in ceh-14 mutants or upon CEH-14 overexpression.

• Validation in human/mammalian systems: Test whether mammalian orthologs of CEH-14 targets are regulated by LHX3/LHX4, the vertebrate counterparts of CEH-14 .

Why might CEH-14 antibody staining not match reporter gene expression patterns?

When CEH-14 antibody staining doesn't match reporter gene expression patterns, consider these potential explanations and solutions:

• Post-transcriptional regulation: The reporter may reflect transcriptional activity while antibody detects actual protein levels, which can differ due to:

  • Translational control mechanisms

  • Protein stability differences

  • miRNA regulation of the endogenous transcript

• Regulatory element exclusion: Reporter constructs may lack distal regulatory elements. Key regulatory regions for ceh-14 expression have been identified within the transcribed region and first large intron (E1), which could be missing in reporters .

• Protein localization signals: The reporter may lack signals that control subcellular localization of the native protein. CEH-14 as a transcription factor would typically show nuclear localization that might not be recapitulated by cytoplasmic GFP reporters.

• Antibody limitations:

  • Epitope masking in certain cellular contexts

  • Fixation-sensitive epitopes

  • Cross-reactivity with related proteins

• Technical approach:

  • Compare multiple reporter constructs with different regulatory regions

  • Generate a knock-in fluorescent tag at the endogenous locus

  • Use different fixation protocols to preserve epitopes

  • Test antibodies raised against different regions of CEH-14

The presence of ncRNAs within conserved regulatory regions of ceh-14 (in A3 and E1) could potentially affect translation or stability of the endogenous transcript but not the reporter .

How can AI-based structural prediction tools assist in developing more specific CEH-14 antibodies?

Advanced AI-based structural prediction tools can revolutionize CEH-14 antibody development through these methodological approaches:

• Epitope optimization: AI algorithms can predict surface-exposed, immunogenic regions of CEH-14 that are distinct from related LIM homeodomain proteins, increasing antibody specificity. This approach parallels recent advances in de novo antibody design, where AI models can design complementarity-determining regions (CDRs) with high target specificity .

• Structural interface modeling: Tools similar to those used for trastuzumab-HER2 interactions can predict the binding interface between CEH-14 and candidate antibody sequences, allowing selection of designs with optimal complementarity .

• Naturalness scoring: Apply naturalness metrics similar to those used in de novo antibody design to evaluate candidate anti-CEH-14 antibodies, identifying sequences with favorable biophysical properties while maintaining specificity .

• Cross-reactivity prediction: AI models can analyze potential cross-reactivity with other C. elegans proteins, particularly other LIM homeodomain proteins, to minimize off-target binding.

• Stability optimization: Predict modifications that enhance antibody stability under experimental conditions typically used in C. elegans research, such as fixation protocols and buffer systems.

The integration of these computational approaches can significantly accelerate development of highly specific CEH-14 antibodies while reducing empirical screening efforts, similar to how AI has enabled zero-shot design of antibodies against other targets .

What are the best approaches for using CEH-14 antibodies in multiplexed imaging experiments?

For multiplexed imaging with CEH-14 antibodies in C. elegans research:

• Antibody selection and validation:

  • Choose CEH-14 antibodies raised in different host species than other target antibodies

  • Validate specificity using absorption controls for each antibody individually

  • Test for cross-reactivity between secondary antibodies

• Multiplexed immunofluorescence strategies:

  • Sequential immunostaining: Apply, image, and strip each antibody sequentially using glycine buffer (pH 2.5) or SDS buffer

  • Spectral unmixing: Use confocal microscopy with spectral detection to separate overlapping fluorophore emissions

  • Immunoglobulin subtype selection: Use primary antibodies of different IgG subtypes with subtype-specific secondaries

• Imaging platform selection:

  • Confocal microscopy with sequential scanning to minimize bleed-through

  • Light-sheet microscopy for whole-animal imaging with reduced photobleaching

  • Super-resolution techniques (STED, STORM) for co-localization at sub-diffraction resolution

• Analysis approaches:

  • Quantify co-localization using Pearson's or Mander's coefficients

  • Implement 3D reconstruction of expression patterns

  • Apply object-based analysis to quantify relationships between CEH-14-positive cells and other labeled structures

• Tissue-clearing techniques:

  • Use CLARITY, CUBIC, or Scale methods adapted for C. elegans to improve antibody penetration and optical transparency

This approach has been successfully used in other contexts, such as mapping phoenixin-14 immunoreactivity across multiple brain regions and peripheral tissues simultaneously .

How can I use CEH-14 antibodies to investigate potential noncoding RNA regulation of ceh-14 expression?

To investigate noncoding RNA regulation of ceh-14 expression using CEH-14 antibodies:

• Combined RNA FISH and immunofluorescence:

  • Design probes targeting the two predicted ncRNAs identified in conserved regions A3 and E1 of the ceh-14 locus

  • Perform sequential RNA FISH followed by CEH-14 immunostaining

  • Analyze spatial correlation between ncRNA expression and CEH-14 protein levels

• ncRNA perturbation and protein quantification:

  • Design CRISPR-Cas9 deletion or modification of the ncRNA loci without disrupting coding sequences

  • Quantify changes in CEH-14 protein levels via immunoblotting or quantitative immunofluorescence

  • Compare tissue-specific effects, particularly in hypodermis where expression shows a gradient pattern

• Pull-down experiments:

  • Use biotinylated antisense oligonucleotides to capture the ncRNAs

  • Perform mass spectrometry to identify proteins that interact with these ncRNAs

  • Investigate whether these proteins interact with CEH-14 or regulate its expression

• Temporal analysis of expression:

  • Track developmental timing of ncRNA expression versus CEH-14 protein accumulation

  • Determine if ncRNAs act as precursors or feedback regulators of CEH-14 expression

• Cross-species conservation analysis:

  • Determine if similar ncRNAs exist near Lhx3/Lhx4 loci in vertebrates

  • Assess conservation of regulatory mechanisms across species

This research direction is particularly promising since ncRNAs have been predicted by modENCODE in the well-conserved areas A3 and E1 of the ceh-14 locus, transcribed in the opposite direction of ceh-14 .

What control experiments are essential when using CEH-14 antibodies in neutralization assays?

When employing CEH-14 antibodies in neutralization assays, implement these essential controls:

• Isotype controls: Include matched isotype control antibodies at equivalent concentrations to account for non-specific effects of immunoglobulins. This approach parallels standard practice in neutralization assays such as the Focus Reduction Neutralization Test (FRNT) .

• Absorption controls: Pre-incubate CEH-14 antibody with purified antigen to confirm signal elimination, similar to validation approaches used for other research antibodies .

• Dilution series: Perform serial dilutions of antibody to establish dose-response curves and calculate median neutralizing dilution (ND50) using Probit regression analysis as demonstrated in FRNT protocols .

• Cross-reactivity tests: Evaluate potential cross-neutralization of related LIM-homeodomain proteins, particularly other C. elegans LIM homeobox proteins.

• Temporal controls: If studying developmental processes, include stage-matched samples to account for natural variation in CEH-14 expression levels during development.

• Reporter system validation: Confirm that your reporter system accurately reflects CEH-14 activity by comparing with independent measures of CEH-14 function.

• Statistical analysis: Apply mixed-effects linear models to log-transformed neutralization titers to properly account for experimental variability .

This methodological approach ensures robust, quantitative assessment of specific antibody effects with appropriate controls for non-specific binding and experimental variation.

How should CEH-14 antibody data be quantified for publication-quality results?

For publication-quality quantification of CEH-14 antibody data:

• Standardized image acquisition:

  • Use identical microscope settings across all experimental conditions

  • Include fluorescence standards in imaging sessions for normalization

  • Acquire z-stacks with consistent step sizes when imaging tissues with 3D structure

• Rigorous quantification methods:

  • For intensity analysis: Measure mean fluorescence intensity in defined regions of interest with appropriate background subtraction

  • For pattern analysis: Implement gradient quantification by measuring intensity along defined transects across tissues

  • For co-localization: Calculate Mander's or Pearson's correlation coefficients between CEH-14 and other markers

• Statistical approach:

  • Use mixed-effects models to account for biological and technical variation

  • Transform data appropriately (e.g., log transformation) when needed for statistical validity

  • Include sufficient biological replicates (typically n≥3 independent experiments)

  • Report exact p-values and confidence intervals rather than significance thresholds

• Visualization standards:

  • Present representative images alongside quantification

  • Use consistent pseudocoloring across figures

  • Include scale bars on all images

  • Show both merged and single-channel images for co-localization experiments

• Reporting guidelines:

  • Document antibody source, catalog number, lot number, and dilution

  • Specify all image processing steps and parameters

  • Provide acquisition details (exposure times, gain settings, etc.)

  • Make raw data available upon request or in public repositories

This approach follows best practices in antibody-based research and ensures reproducibility and reliability of published CEH-14 findings.